Please complete as many details as possible and forward within one business day

Program Details													
Form Completed By					Name of Program:								
Print Name:	ANGELA MURADYAN				TREATMENT OF HCV PATIENTS WITH DONATED "SOVALDI" MEDICINE IN THE REPUBLIC OF ARMENIA								
Signature:	Signature:				Name of Organisation:								
Telephone Number:					"NORK" REPUBLICAN INFECTIOUS CLINICAL HOSPITAL								
					Date aware of Safety Information: 20/06/2017								
Fax No/Email:					Country of Occurrence of Safety Information; ARMENIA								
Patient Details													
DOB:	(or year of birth):		Sex:	Male		Female		Init	ials: /	λA	Age:	49	
Drug Details	(Provide additional drugs on a se	eparate page)											
Lot/Batch No	Reason For Taking	Stop Date (or (DD/MON/Y		(Start Date (DD/MON/YYYY)		Route		Dose		Drug Name		
N/A	нер с	21/06/2	017		15/06/2017		РО		400MG		SOVALDI		
N/A	НЕР С	21/06/2	017		15/06/2017		РО		60MG		DAKLATA	DAKLATASVIR	
Safety Information Details: Please provide a short summary of the adverse event(s) (AE) or other safety information (e.g. reports such as pregnancy, death, hospitalization, overdose, misuse, abuse, medication error, lack of effect, off-label use, occupational exposure, AEs associated with product complaints or AEs in an infant following exposure from breastfeeding). Please include the start and stop dates and the outcome of the event(s) or confirm if the event(s) is/are still ongoing. Please also provide any treatment given to treat the event(s), any relevant medical history and for reports of death include the date of death – continue on another page if necessary.										ollowing			
On 15.06.2017 patient started treatment with Sovaldi and daklatasvir and on the 5 th day of medicine intake patient experienced facial oedema, suffocation feeling and angioedema. Patient was immediately administered dimedrol 1g/ml for AE correction. The symptoms of AE expired the same day. Patient mentioned that in past he was experiencing allergic reactions with other drugs as well.													
	formation previously been rep Yes □ No ☑		ulatory		Does the drug?		er consi es ☑	der th	nat the event(No [e possibly rela	ated to the	
Reporter De	tails (i.e. who notified you of	the above safe	ety informa	ation?)									
Is the Reporter is	a: Doctor ☑ Nurse s a Healthcare Professional	(HCP) and the	ey are will			•		٠, ٠)). o pmatient, rel tinformation,	,		'ow	
*If the Reporter is a Non-healthcare professional, please confirm if they are willing to provide contact information for their HCP: Yes □ P lease record HCP details be bw) No □													
HCP Address					HCP Na	ame:							
First Line:					HCP Te	olophone	No/E/	V N					
Town/City:						•	= NO/F	AA ING	J.				
HCP Email: County/State:													
Postcode/Zip co	de:												
DI I	1	1 361 1 .	C T 1	77 1.	.1 1.0	. 1 4 00			(1.6 T.T.C.A.)	1			

Please be aware that information provided to the Ministry of Labour, Health and Social Affairs of Georgia(MoLHSA) relating to you, may be used to comply with applicable laws and regulations. By providing us with information you are consenting to the control and processing of this personal or sensitive data by MoLHSA in accordance with applicable data protection laws and the MoLHSA privacy policy.